ReviewESC heart failure2026
Heart failure and cognitive impairment: a narrative review.
Review in ESC heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Heart failure (HF) is a major global health burden affecting more than 64 million individuals worldwide, and is associated with substantial morbidity, mortality, and healthcare expenditure. Cognitive impairment (CI) is a prevalent and clinically consequential comorbidity, affecting approximately 40%-50% of patients with HF across both reduced and preserved ejection fraction phenotypes. Despite its high prevalence and adverse prognostic implications, CI remains systematically underdiagnosed and insufficiently addressed in routine clinical practice. The pathophysiological mechanisms linking HF and CI are multifactorial and incompletely understood, encompassing cerebral hypoperfusion secondary to reduced cardiac output, systemic neuroinflammation driven by pro-inflammatory cytokines, oxidative stress, neurohumoral dysregulation, and cerebrovascular injury. Shared cardiovascular risk factors, including atrial fibrillation, hypertension, diabetes mellitus, and obesity, further compound the risk of cognitive decline. CI exerts a profound impact on clinical outcomes in HF, independently predicting increased all-cause mortality, higher rates of hospitalization and 30-day readmission, impaired self-care capacity, and reduced medication adherence. Early and systematic identification is a reasonable clinical priority that may support optimized clinical management and informed shared decision-making. This review synthesizes current evidence on the epidemiology, pathophysiology, clinical assessment, prognostic significance, and therapeutic implications of CI in HF, and highlights key controversies and priorities for future research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.